Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Living the dream! Stay safe my friend…
All is great as I'm back in thailand after a month in Laos.
VCIG These bargain prices are insane IMO.
$AGBA ~ PPS target is $10.00+ when merger press drops.
Morning, Can’t wait for September to be over. Looking forward to the next few months. Its my Friday getting off work in an hour. I'm Ready for the weekend. Hope all is well Easy…
Hi,hope your ready with your crypto qe getting close for bitcoin breakout imo probably in a few weeks if not sooner.
$VCIG .14 This stock is shaping up to be a monster. With a net profit per share of 16 cents, it’s currently trading below that figure. It has a low float and insiders hold over 50% of the outstanding shares. Just a week ago, they announced an $18M contract, and not long before that, they revealed a $10M buyback. The CEO also increased their shareholding by 15.27% of the total outstanding shares.
Additionally, the company reported a 44% year-over-year revenue increase, a 57% rise in gross profit, and net income surged to $5.4M, reflecting a remarkable 25% growth. These results align with our full-year guidance of a 65% revenue increase and a 68% rise in gross profit for fiscal year 2024.
The company has until mid-December to push the stock price above $1, with a potential 180-day extension available. Imho.
Out $RR. Great ride. Into $PDYN: Palladyne AI Robotics. AI software for robots & robotics.
muln...................................................
Volt's commercial vehicle order of 3000 Class 1 & 3 EV cargo vans and trucks will be assembled at Mullen’s Tunica, Mississippi-based Commercial Vehicle Facility.
— Mullen Automotive (@Mullen_USA) August 26, 2024
First round of deliveries to being immediately!⚡🚚🚐 pic.twitter.com/QZVVoUWL06
LUMN........ZVIA..........GOVX.........https://www.stockscores.com/charts/charts/?ticker=GOVX
https://www.stockscores.com/charts/charts/?ticker=ZVIA
https://www.stockscores.com/charts/charts/?ticker=LUMN
FFIE......................MULN............................PSNY.........https://stockcharts.com/h-sc/ui?s=FFIE&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=PSNY&p=D&yr=0&mn=2&dy=12&id=p84071410134
IVP........MULN...............................................https://www.globenewswire.com/news-release/2024/08/06/2924991/0/en/Mullen-CEO-Provides-Company-Update.html
NSAV THE GOLDEN TICKET $$$$$$
Net Savings Link, Inc.
Common Stock
0.0044
0.0044 / 0.0045 (1 x 1)
Real-Time Best Bid & Ask: 10:50am 08/02/2024
Delayed (15 Min) Trade Data: 10:29am 08/02/2024
Overview
Quote
Company Profile
Security Details
News
Financials
Disclosure
Research
OTC DISCLOSURE & NEWS SERVICE
NSAV Announces NSAVx.com CEX Exchange and Airdropx Updates
Press Release | 08/02/2024
Net Savings Link, Inc. (OTC: NSAV), a leading Web3, blockchain, and digital asset technology company, announced today a strategic focus on NSAVx.com Centralized Cryptocurrency Exchange (CEX) https://nsavx.com/ and Airdropx.
Key Updates:
Revenue Focus:
NSAVx.com: Experiencing significant growth from institutional customers.
Airdropx: Achieving over 90% profit margins, making it the company's largest profit center.
Target Marketing Campaign:
Starting August 1, 2024: NSAV will target high-net-worth crypto investors, hedge funds, family offices,
and crypto clubs to increase institutional clients on NSAVx.com, aiming to boost transaction revenue by Q4 2024.
Airdrop Campaign: Offering 25,000 crypto projects their first month free for airdrops, with a goal to reach 1,500 airdrops by Q4, potentially generating $12 million in annual free cash flow.
The company will maintain its focus on institutional clients while expanding its retail consumer base of over 9 million non-active customers. The NSAV marketing team plans to convert non-active customers to active users through coordinated giveaways, tournaments, airdrops, and exchange incentives, including events.
Rebranding and Streamlining:
Airdropx Rebranding: Airdropx will be rebranded with a new NSAVx.com login for airdrop projects, streamlining the airdrop process for projects and their existing wallet holders.
NSAvip Holder Benefits: Effective August 1, 2024, all NSAvip holders will participate in each airdrop project listed on Airdropx.
Kevin Simon, CMO of NSAV, stated, "We see target marketing as the fastest way to grow our client base. By having over 9 million accounts on the CEX exchange, we have an audience of potential customers we can convert to active users. With direct email, social media, and coordinated videos, we are confident that we can get NSAVx.com and Airdropx in front of qualified customers converting them to active users, who will quickly gravitate to using our unique crypto platform."
About Net Savings Link, Inc.: NSAV's vision is the establishment of a fully integrated technology company, which provides turnkey technological solutions to the Web3, blockchain and digital asset industries. The Company drives innovation in the digital currency space by developing advanced blockchain technologies, digital assets, and market solutions that bridge the gap between traditional business frameworks and the future of decentralized technology. The Company currently offers a wide range of services including software solutions, e-commerce, financial services, advisory services and information technology.
For further information please contact NSAV at info@nsavholdinginc.com
For further information please contact NSAVx.com at hello@nsavxmail.com
The NSAV corporate website can be accessed at https://www.netsavingslinkinc.com
The NSAV CEX website can be accessed at https://nsavx.com/
TheAlley.io can be accessed at https://www.thealley.io
The AirdropX.co website can be accessed at https://www.airdropx.co/
The Swopx.io website can be accessed at https://www.swopx.io
The NSAV Stock information website can be accessed at https://www.nsavstock.com
The NSAVx Token website can be accessed at https://www.nsavxtoken.com/nsavx-token
The NSAVx Discord Server can be accessed at https://discord.com/invite/7Q2Vv5NmKd
The NSAV Twitter account can be accessed at https://twitter.com/nsav_tech
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.
Contact
Net Savings Link, Inc.
info@nsavholdinginc.com
$SXTC @ $1.14.. Has $15.75 a share cash. 986K total shares. Social media posts rising. Up on strong volume in pre-market. Mob attack on tap?...Heads up!
$SERV & $AYRO @ .83:...5M total shares. 15% short. Has $7.38 a share cash...In that same low speed EV sector as $SERV..$AYRO 52 week high was $7.50+
.....$AYRO right in that niche
Link:
https://www.ayro.com/
IVP..............................https://stockcharts.com/sc3/ui/?s=IVP&id=p30522489890
$SLRX @ $1.90s: Has $7.28 cash. Tot. shares 620K...Right @ breakout. Big vol. building. NAAS up 180%...Same crowd on SLRX now.
AEON.......AREB.......FFIE...........MULN.........................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=AREB&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=FFIE&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
$QLGN +111% #DDAmanda Video Analysis - #1 Stock Scanner/Screener
$AYRO @ .89: Micro-float EV play with $7.68 a share cash starting to rip on $ZAPP & $IVP crowd buying attack. Big shorts in $AYRO...AHs carnage possible for shorts.
BLNK....EVGO......CHPT............................https://stockcharts.com/h-sc/ui?s=EVGO&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=CHPT&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=BLNK&p=W&b=5&g=0&id=p84354014936
$AYRO @ .70s: Nano-float EV play with $5.68 cash. No debt. $ZAPP and $KOSS Roaring Kitty crowd talking up $AYRO now. Likely launch it big.
$AYRO @ .80: MicroFloat EV play with $5.68 a share cash. History of very big rips. $Koos Roaring Kitty crowd posting about $AVRO now. They did thing with EV play $KOSS last week and sent it into orbit.
DO not miss $AYRO
🔥 $AAGC 🔥 Conference call folks!
🔥🔥 $AAGC 🔥🔥 Conference call folks!! 💪💪 https://t.co/DDdqNdtXFE
— Nickeli (@nickeli54) July 9, 2024
🔥$AAGC 🔥 Mega Thread! 💪
@HStarcuts 🔥🔥🔥 $AAGC 🔥🔥🔥🧵 Folks let’s take a look at where we are here:
— Nickeli (@nickeli54) July 9, 2024
✅ MC= $1M
✅ SS = 1.7B OS
✅ No Dilution
✅ No RS Stated many times
✅ Share buybacks monthly
✅ New Locations opening
✅ Audit underway
✅ Qtr over Qtr growth 🔥
✅Annual showed massive growth YOY pic.twitter.com/Bdy0upLSV5
🔥 $AAGC 🔥
💥 $AAGC 💥 Only takes one stock folks to change your life! 8’s hitting 🔥 patience usually plays well if it’s a 💎 Just have to peel back the onion to see what’s inside and this play is as clean as it gets! Take a peek at this annual and note share buy backs 👀 💎🔥💪 pic.twitter.com/kThR84MOuA
— Nickeli (@nickeli54) July 8, 2024
$EMGE Due Diligences Update:))) Look at the bigger picture here!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174709831
$CATV NEWS: Category V Biotech, Inc. Announces Exclusive Licensing of Genetic Networks' Intellectual Property for Cannabis Applications
FLORIDA, July 2, 2024 – Category V Biotech, Inc. (OTC: CATV), formerly known as 4Cable TV International, Inc., is pleased to announce significant progress in our relationship with Genetic Networks, LLC (https://geneticnetworks.com/).
While continuing to analyze the acquisition, Category V Biotech and Genetic Networks have agreed to allow CATV to become the exclusive licensee of all Genetic Networks’ intellectual property and technology worldwide for cannabis applications. This agreement allows Genetic Networks time to address internal matters found during due diligence, while Category V Biotech begins its journey into the discovery of medicines using cannabis. This licensing agreement will facilitate close collaboration with Genetic Networks on cannabis research and development, positioning Category V Biotech as a leader in developing cannabis medicines.
Our goal is to screen cannabis and cannabis-derived products to determine their medicinal benefits by utilizing Genetic Networks' extensive disease database accumulated over the past decade while working for pharmaceutical companies and government. Discovering the use of cannabis for specific diseases is key to developing medicines that can be registered with regulatory bodies worldwide and distributed for medical use or treatment.
The exclusive licensing of Genetic Networks’ technologies, including their proprietary platform GeneScape™, will facilitate the rapid and unbiased discovery of optimal drug compounds from cannabis through whole-genome analysis. This exclusive license allows Category V Biotech to expand into the biotech sector of the cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.
"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before, as regulated FDA products under the new regulatory environment of the United States." Dr. Gennaro D’Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."
Upon resolving internal matters identified during due diligence, Category V Biotech will complete the acquisition of Genetic Networks. Following the transaction, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global cannabis operations, including cultivation, biotech research, and retail. This transaction culminates years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using cannabis.
The recent changes in the rescheduling of cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, has paved the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the cannabis industry, driving innovation and advancing therapeutic solutions for patients. Category V Biotech remains actively engaged in pursuing additional acquisitions in the cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.
About Genetic Networks, LLC
Established in 2015, Genetic Networks, LLC has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis. About Category V Biotech, Inc. Category V Biotech, Inc. (OTC: CATV) aims to establish and operate a fully integrated global cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical cannabis-based products and therapies.
MBIO...........MULN.........................https://stockcharts.com/h-sc/ui?s=MBIO&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
$AVRW Seratopical skin care products are keeping the famous Nicole Kidman looking her best. Everyone can clearly see this.
When it comes to anti-aging skincare, Kidman's loyalty lies with Seralabs. Kidman, who has been working with the brand since 2020, told InStyle that she “loves using Seratopical because it makes my skin smooth and hydrated.” In honor of the brand ambassador’s birthday, Seralabs is offering 30 percent off sitewide all week with the code NK30.
Source:
https://www.instyle.com/nicole-kidman-birthday-favorite-beauty-products-8666305?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons
$CCTG News: CCSC Technology International Holdings Limited Enters into International Purchase Agreement with SHI / LIGHTCARE-SOLUTIONS ApS
Hong Kong, June 20, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that it has entered into an international purchase agreement (the “Agreement”) with SHI / LIGHTCARE-SOLUTIONS ApS (“SHI”), a Danish company that primarily engages in the design and supply of healthcare lighting products.
Pursuant to the Agreement, CCSC will manufacture and supply healthcare lighting products based on the designs provided by SHI to customers in the Asia Pacific region. Under this Agreement, the parties estimate that the annual purchasing amount will start at €0.50 million (approximately US$0.54 million) in 2025 and increase to €3.50 million (approximately US$3.76 million) in 2030.
Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, “We are thrilled to partner with SHI to expand our healthcare lighting business in the Asia Pacific market. This partnership aligns with our strategic goal of diversifying our product portfolio and expanding our presence in the healthcare sector. Through our collaboration with SHI, we are poised to deliver innovative and effective lighting solutions that meet the needs of customers in the healthcare industry. We believe this collaboration will drive growth for both companies in the foreseeable future.”
About CCSC Technology International Holdings Limited
CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
IMCC.....CLOV............................https://stockcharts.com/h-sc/ui?s=CLOV&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=IMCC&p=W&b=5&g=0&id=p84354014936
CIFR were clsk weee IREN wweeee BTBT waiting
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors
Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology
Retired at a rank that is the civilian equivalent of a senior flag officer from the United States Navy
RADNOR, Pa., June 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has added Dr. Dennis McBride to its Board of Directors. Dr. McBride brings deep experience in Neuroscience, Medical and Information Technology and digital therapeutics to the Company.
"I am delighted to welcome Dennis to the Board of NRx. His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients," said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. "I have worked with Dennis previously on a highly successful digital therapeutic and know the quality he brings to our company."
"I am proud to join the Board of NRx at such an exciting time for the company – the opportunities have never been greater in Neuroscience to advance and improve novel therapies," commented Dr. McBride. "I look forward to using my experience to help advance its strategy and further the development of NRx's impressive pipeline of CNS products and leading its initiative in digital therapeutics."
Dr. Dennis McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development both within the federal government and in the private sector, three of which are now multi-billion-dollar enterprises. He has formative experience in CNS-focused digital therapeutics, having participated with NRx founders in developing now military-proven digital therapeutic technology for reduction of stress and depression. He was instrumental to the founding of InQTel and other private sector-focused initiatives.
Dr. McBride dedicated his Navy career to Aerospace Medicine and ergonomics, during which he served in leadership roles at six nationally-prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated Navy Captain, he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. He then joined the National Defense University as a Professor to lead the Center for Technology and National Security Policy, completing his term as a Senior Executive-4 (Civilian equivalent to Vice Admiral). Most recently, he served a tour of duty in the Office of the Secretary of Defense. Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes the University of Georgia, Naval Aerospace Medical Institute, the University of Southern California, the London School of Economics, and Harvard Business School, earning a Ph.D. in experimental psychology and four master's degrees.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL42013&sd=2024-06-18 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-appoints-neuroscience-information-technology-and-medical-technology-veteran-to-its-board-of-directors-302175147.html
SOURCE NRx Pharmaceuticals, Inc.
DHAI.............................BRFH........................................https://stockcharts.com/h-sc/ui?s=DHAI&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=BRFH&p=D&yr=0&mn=2&dy=12&id=p84071410134
$AVRW: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
RETO.....REBN......MULN......GOEV.......https://stockcharts.com/h-sc/ui?s=GOEV&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=REBN&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=RETO&p=D&yr=0&mn=2&dy=12&id=p84071410134
Some buying volume is hitting on UCPA
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression and suicidality
Presenters from 3 open label studies at the ASCP suggested that intravenous ketamine is at least equivalent and may have advantages over intranasal S-ketamine
NRx Pharmaceuticals has now reached the 9-month stability point with its ketamine formulation (NRX-100) and has initiated 3 manufacturing lots for future drug release. Nonclinical safety for short term use of NRX-100 has recently been published and submitted to FDA
FDA leadership, in public comments at ASCP, focused on the need for nonclinical safety data for intravenous ketamine as a condition of ketamine approval
The short-term need for intravenous ketamine as an already-approved, schedule 3 drug, is heightened by recent regulatory decisions that may delay the path of potent, schedule 1 psychedelic drugs that may require more complicated clinical trial designs.
RADNOR, Pa., June 10, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new Shareholder Update Letter on its website NRx Shareholder Update and further invites interested parties to subscribe to their email alert service to stay up to date on company's progress here: NRx Email Alerts . (Note: not all updates will be included in a Press Release in the future).
Today's update highlights potential implications of the Company's recent activities at the annual meeting of the American Society of Clinical Psychopharmacology. The key points include:
Intravenous and intranasal ketamine were highlighted as emerging standards of care for severe depression and suicidality
Planned NDA filing for NRX-100, our preservative free IV ketamine, for Suicidal Depression in 2024, is based on well controlled trials against both placebo and active comparator. Fast Track Designation was previously granted
An independent FDA advisory panel recently voted against MDMA, a potent, class I psychedelic, refocusing attention on already-approved Schedule 3 drugs such as ketamine for treatment of suicidal depression. The FDA panel and emerging guidance highlights the complexity of clinical trials of DEA Schedule 1 hallucinogens that do not have already-approved human uses
NRx anticipates that an important issue for longer term use of ketamine in depression will be the current multidose vial presentation that contains potentially toxic preservatives previously acceptable for one time use but less suitable for repeated use. NRX-100 is planned as a single-dose, preservative-free medication.
Please subscribe to the Company's email for future updates. NRX Email Alerts Not all of these will be the subject of a Press Release in the future.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine), in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals, focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
It states that the merger is contingent upon minority shareholder approval. I'm hoping minority shareholders are able to negotiate a better price for shares.
Completion of the Merger will be subject to approval by the stockholders of UCP in accordance with the requirements of Nevada merger law (the "Statutory Merger Shareholder Approval"). In addition, completion of the Merger will be subject to approval by a majority of shares held by shareholders of UCP who are present and eligible to vote at the meeting of shareholders to be held to approve the Merger, other than MSMA and its affiliates (the "Minority Shareholder Approval").
Followers
|
489
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27444
|
Created
|
07/08/16
|
Type
|
Free
|
Moderator powerbattles | |||
Assistants easymoney ABCtrader1027 blanka $Pistol Pete$ |
Posts Today
|
0
|
Posts (Total)
|
27444
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |